Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE versus OTICAIR.
Betamethasone vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression, resulting in anti-inflammatory and immunosuppressive effects. It also suppresses the hypothalamic-pituitary-adrenal axis.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
0.6 to 9 mg/day orally in divided doses; intramuscularly, 0.5 to 9 mg/day; intravenously, up to 12 mg/day; topical (as valerate or dipropionate) applied thinly to affected area once to twice daily.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Clinical Note
moderateBetamethasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin."
Clinical Note
moderateBetamethasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin."
Clinical Note
moderateBetamethasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 6.4 hours (range 4.3-9.4 hours). Clinically, adrenal suppression lasts 2.7-3.5 days after single dose.
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Primarily renal: ~60% as metabolites, <5% unchanged. Biliary/fecal: ~15-20%.
Renal: 85% unchanged; biliary/fecal: 10%
Category A/B
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid
Betamethasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin."